Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Mitsuyasu

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2018
A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium TrialStephen E Goldstone, Shelly Y Lensing, Elizabeth A Stier, et al.
The Journal of Infectious Diseases|January 29, 2003
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046sHernan Valdez, Ronald Mitsuyasu, Alan Landay, et al.
AIDS Research and Therapy|November 4, 2011
The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatmentSanjeev Sinha, Sahajal Dhooria, Sanjiv Kumar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2016
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H Borges, Jacqueline Neuhaus, Abdel G Babiker, et al.
The Journal of Infectious Diseases|November 17, 2006
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby, R Pat Bucy, Donna Mildvan, et al.
Archives of Internal Medicine|March 29, 2007
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, et al.
AIDS Research and Human Retroviruses|June 25, 2002
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha, Hernan Valdez, Rebecca S Gelman, et al.
Cancer|November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 StudyLakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 31, 2018
A Randomized Clinical Trial of Infrared Coagulation Ablation Versus Active Monitoring of Intra-anal High-grade Dysplasia in Adults With Human Immunodeficiency Virus Infection: An AIDS Malignancy Consortium TrialStephen E Goldstone, Shelly Y Lensing, Elizabeth A Stier, et al.
The Journal of Infectious Diseases|January 29, 2003
Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046sHernan Valdez, Ronald Mitsuyasu, Alan Landay, et al.
AIDS Research and Therapy|November 4, 2011
The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatmentSanjeev Sinha, Sahajal Dhooria, Sanjiv Kumar, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2016
Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV InfectionÁlvaro H Borges, Jacqueline Neuhaus, Abdel G Babiker, et al.
The Journal of Infectious Diseases|November 17, 2006
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby, R Pat Bucy, Donna Mildvan, et al.
Archives of Internal Medicine|March 29, 2007
The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328Ronald Mitsuyasu, Rebecca Gelman, Deborah Weng Cherng, et al.
AIDS Research and Human Retroviruses|June 25, 2002
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha, Hernan Valdez, Rebecca S Gelman, et al.
Cancer|November 14, 2023
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 StudyLakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu Joshi, et al.
Blood|May 21, 2020
Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)Juan C Ramos, Joseph A Sparano, Amy Chadburn, et al.
The Lancet. Haematology|August 2, 2023
Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trialPaul G Rubinstein, Page C Moore, Milan Bimali, et al.
Pageof 5